

**BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA**

**In the Matter of the Accusation Against**

**Alan Ogden Marcus, M.D.**

**Physician's and Surgeon's  
License No. A39696**

**Respondent.**

**Case No. 800-2016-024668**

**DECISION**

**The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.**

**This Decision shall become effective at 5:00 p.m. on July 3, 2020.**

**IT IS SO ORDERED: June 4, 2020.**

**MEDICAL BOARD OF CALIFORNIA**



---

**Kristina D. Lawson, J.D., Chair  
Panel B**

1 XAVIER BECERRA  
Attorney General of California  
2 ALEXANDRA M. ALVAREZ  
Supervising Deputy Attorney General  
3 KEITH C. SHAW  
Deputy Attorney General  
4 State Bar No. 227029  
600 West Broadway, Suite 1800  
5 San Diego, CA 92101  
P.O. Box 85266  
6 San Diego, CA 92186-5266  
Telephone: (619) 738-9515  
7 Facsimile: (619) 645-2012

8 *Attorneys for Complainant*

9  
10 **BEFORE THE**  
**MEDICAL BOARD OF CALIFORNIA**  
11 **DEPARTMENT OF CONSUMER AFFAIRS**  
12 **STATE OF CALIFORNIA**

13 In the Matter of the Accusation Against:

Case No. 800-2016-024668

14 **ALAN OGDEN MARCUS, M.D.**

OAH No. 2019100622

15 24422 Avenida De La Carlota, Suite 375  
16 Laguna Hills, CA 92653

**STIPULATED SETTLEMENT AND  
DISCIPLINARY ORDER**

17 **Physician's and Surgeon's Certificate No.**  
18 **A 39696**

Respondent.

19  
20 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
21 entitled proceedings that the following matters are true:

22 **PARTIES**

23 1. Christine J. Lally (Complainant) is the Interim Executive Director of the Medical  
24 Board of California (Board). She brought this action solely in her official capacity and is  
25 represented in this matter by Xavier Becerra, Attorney General of the State of California, by  
26 Keith C. Shaw, Deputy Attorney General.

27 2. Respondent Alan Ogden Marcus, M.D., is represented in this proceeding by attorney  
28 Raymond J. McMahon, Esq., whose address is: 5440 Trabuco Road, Irvine, CA 92620.







1 Respondent shall provide proof of attendance for 65 hours of CME of which 40 hours were in  
2 satisfaction of this condition.

3 3. PRESCRIBING PRACTICES COURSE. Within 60 calendar days of the effective  
4 date of this Decision, Respondent shall enroll in a course in prescribing practices approved in  
5 advance by the Board or its designee. Respondent shall provide the approved course provider  
6 with any information and documents that the approved course provider may deem pertinent.  
7 Respondent shall participate in and successfully complete the classroom component of the course  
8 no later than six (6) months after Respondent's initial enrollment. Respondent shall successfully  
9 complete any other component of the course within one (1) year of enrollment. The prescribing  
10 practices course shall be at Respondent's expense and shall be in addition to the Continuing  
11 Medical Education (CME) requirements for renewal of licensure.

12 A prescribing practices course taken after the acts that gave rise to the charges in the  
13 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
14 or its designee, be accepted towards the fulfillment of this condition if the course would have  
15 been approved by the Board or its designee had the course been taken after the effective date of  
16 this Decision.

17 Respondent shall submit a certification of successful completion to the Board or its  
18 designee no later than 15 calendar days after successfully completing the course, or no later than  
19 15 calendar days after the effective date of the Decision, whichever is later.

20 4. MEDICAL RECORD KEEPING COURSE. Within 60 calendar days of the effective  
21 date of this Decision, Respondent shall enroll in a course in medical record keeping approved in  
22 advance by the Board or its designee. Respondent shall provide the approved course provider  
23 with any information and documents that the approved course provider may deem pertinent.  
24 Respondent shall participate in and successfully complete the classroom component of the course  
25 no later than six (6) months after Respondent's initial enrollment. Respondent shall successfully  
26 complete any other component of the course within one (1) year of enrollment. The medical  
27 record keeping course shall be at Respondent's expense and shall be in addition to the Continuing  
28 Medical Education (CME) requirements for renewal of licensure.

1 A medical record keeping course taken after the acts that gave rise to the charges in the  
2 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
3 or its designee, be accepted towards the fulfillment of this condition if the course would have  
4 been approved by the Board or its designee had the course been taken after the effective date of  
5 this Decision.

6 Respondent shall submit a certification of successful completion to the Board or its  
7 designee no later than 15 calendar days after successfully completing the course, or no later than  
8 15 calendar days after the effective date of the Decision, whichever is later.

9 5. PROFESSIONALISM PROGRAM (ETHICS COURSE). Within 60 calendar days of  
10 the effective date of this Decision, Respondent shall enroll in a professionalism program, that  
11 meets the requirements of Title 16, California Code of Regulations (CCR) section 1358.1.  
12 Respondent shall participate in and successfully complete that program. Respondent shall  
13 provide any information and documents that the program may deem pertinent. Respondent shall  
14 successfully complete the classroom component of the program no later than six (6) months after  
15 Respondent's initial enrollment, and the longitudinal component of the program no later than the  
16 time specified by the program, but no later than one (1) year after attending the classroom  
17 component. The professionalism program shall be at Respondent's expense and shall be in  
18 addition to the Continuing Medical Education (CME) requirements for renewal of licensure.

19 A professionalism program taken after the acts that gave rise to the charges in the  
20 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
21 or its designee, be accepted towards the fulfillment of this condition if the program would have  
22 been approved by the Board or its designee had the program been taken after the effective date of  
23 this Decision.

24 Respondent shall submit a certification of successful completion to the Board or its  
25 designee no later than 15 calendar days after successfully completing the program or no later than  
26 15 calendar days after the effective date of the Decision, whichever is later.

27 6. MONITORING - PRACTICE. Within 30 calendar days of the effective date of this  
28 Decision, Respondent shall submit to the Board or its designee for prior approval as a practice

1 monitor(s), the name and qualifications of one or more licensed physicians and surgeons whose  
2 licenses are valid and in good standing, and who are preferably American Board of Medical  
3 Specialties (ABMS) certified. A monitor shall have no prior or current business or personal  
4 relationship with Respondent, or other relationship that could reasonably be expected to  
5 compromise the ability of the monitor to render fair and unbiased reports to the Board, including  
6 but not limited to any form of bartering, shall be in Respondent's field of practice, and must agree  
7 to serve as Respondent's monitor. Respondent shall pay all monitoring costs.

8 The Board or its designee shall provide the approved monitor with copies of the Decision(s)  
9 and Accusation(s), and a proposed monitoring plan. Within 15 calendar days of receipt of the  
10 Decision(s), Accusation(s), and proposed monitoring plan, the monitor shall submit a signed  
11 statement that the monitor has read the Decision(s) and Accusation(s), fully understands the role  
12 of a monitor, and agrees or disagrees with the proposed monitoring plan. If the monitor disagrees  
13 with the proposed monitoring plan, the monitor shall submit a revised monitoring plan with the  
14 signed statement for approval by the Board or its designee.

15 Within 60 calendar days of the effective date of this Decision, and continuing throughout  
16 probation, Respondent's practice shall be monitored by the approved monitor. Respondent shall  
17 make all records available for immediate inspection and copying on the premises by the monitor  
18 at all times during business hours and shall retain the records for the entire term of probation.

19 If Respondent fails to obtain approval of a monitor within 60 calendar days of the effective  
20 date of this Decision, Respondent shall receive a notification from the Board or its designee to  
21 cease the practice of medicine within three (3) calendar days after being so notified. Respondent  
22 shall cease the practice of medicine until a monitor is approved to provide monitoring  
23 responsibility.

24 The monitor(s) shall submit a quarterly written report to the Board or its designee which  
25 includes an evaluation of Respondent's performance, indicating whether Respondent's practices  
26 are within the standards of practice of medicine, and whether Respondent is practicing medicine  
27 safely, billing appropriately or both. It shall be the sole responsibility of Respondent to ensure  
28 that the monitor submits the quarterly written reports to the Board or its designee within 10



1 calendar days after the end of the preceding quarter.

2 If the monitor resigns or is no longer available, Respondent shall, within five (5) calendar  
3 days of such resignation or unavailability, submit to the Board or its designee, for prior approval,  
4 the name and qualifications of a replacement monitor who will be assuming that responsibility  
5 within 15 calendar days. If Respondent fails to obtain approval of a replacement monitor within  
6 60 calendar days of the resignation or unavailability of the monitor, Respondent shall receive a  
7 notification from the Board or its designee to cease the practice of medicine within three (3)  
8 calendar days after being so notified. Respondent shall cease the practice of medicine until a  
9 replacement monitor is approved and assumes monitoring responsibility.

10 In lieu of a monitor, Respondent may participate in a professional enhancement program  
11 approved in advance by the Board or its designee that includes, at minimum, quarterly chart  
12 review, semi-annual practice assessment, and semi-annual review of professional growth and  
13 education. Respondent shall participate in the professional enhancement program at Respondent's  
14 expense during the term of probation.

15 7. NOTIFICATION. Within seven (7) days of the effective date of this Decision, the  
16 Respondent shall provide a true copy of this Decision and Accusation to the Chief of Staff or the  
17 Chief Executive Officer at every hospital where privileges or membership are extended to  
18 Respondent, at any other facility where Respondent engages in the practice of medicine,  
19 including all physician and locum tenens registries or other similar agencies, and to the Chief  
20 Executive Officer at every insurance carrier which extends malpractice insurance coverage to  
21 Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15  
22 calendar days.

23 8. SUPERVISION OF PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE  
24 NURSES. During probation, Respondent is prohibited from supervising physician assistants and  
25 advanced practice nurses.

26 9. OBEY ALL LAWS. Respondent shall obey all federal, state and local laws, all rules  
27 governing the practice of medicine in California and remain in full compliance with any court  
28 ordered criminal probation, payments, and other orders.

1           10. QUARTERLY DECLARATIONS. Respondent shall submit quarterly declarations  
2 under penalty of perjury on forms provided by the Board, stating whether there has been  
3 compliance with all the conditions of probation.

4           Respondent shall submit quarterly declarations no later than 10 calendar days after the end  
5 of the preceding quarter.

6           11. GENERAL PROBATION REQUIREMENTS.

7           Compliance with Probation Unit

8           Respondent shall comply with the Board's probation unit.

9           Address Changes

10          Respondent shall, at all times, keep the Board informed of Respondent's business and  
11 residence addresses, email address (if available), and telephone number. Changes of such  
12 addresses shall be immediately communicated in writing to the Board or its designee. Under no  
13 circumstances shall a post office box serve as an address of record, except as allowed by Business  
14 and Professions Code section 2021(b).

15          Place of Practice

16          Respondent shall not engage in the practice of medicine in Respondent's or patient's place  
17 of residence, unless the patient resides in a skilled nursing facility or other similar licensed  
18 facility.

19          License Renewal

20          Respondent shall maintain a current and renewed California physician's and surgeon's  
21 license.

22          Travel or Residence Outside California

23          Respondent shall immediately inform the Board or its designee, in writing, of travel to any  
24 areas outside the jurisdiction of California which lasts, or is contemplated to last, more than thirty  
25 (30) calendar days.

26          In the event Respondent should leave the State of California to reside or to practice  
27 ,Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of  
28 departure and return.

1           12. INTERVIEW WITH THE BOARD OR ITS DESIGNEE. Respondent shall be  
2 available in person upon request for interviews either at Respondent's place of business or at the  
3 probation unit office, with or without prior notice throughout the term of probation.

4           13. NON-PRACTICE WHILE ON PROBATION. Respondent shall notify the Board or  
5 its designee in writing within 15 calendar days of any periods of non-practice lasting more than  
6 30 calendar days and within 15 calendar days of Respondent's return to practice. Non-practice is  
7 defined as any period of time Respondent is not practicing medicine as defined in Business and  
8 Professions Code sections 2051 and 2052 for at least 40 hours in a calendar month in direct  
9 patient care, clinical activity or teaching, or other activity as approved by the Board. If  
10 Respondent resides in California and is considered to be in non-practice, Respondent shall  
11 comply with all terms and conditions of probation. All time spent in an intensive training  
12 program which has been approved by the Board or its designee shall not be considered non-  
13 practice and does not relieve Respondent from complying with all the terms and conditions of  
14 probation. Practicing medicine in another state of the United States or Federal jurisdiction while  
15 on probation with the medical licensing authority of that state or jurisdiction shall not be  
16 considered non-practice. A Board-ordered suspension of practice shall not be considered as a  
17 period of non-practice.

18           In the event Respondent's period of non-practice while on probation exceeds 18 calendar  
19 months, Respondent shall successfully complete the Federation of State Medical Board's Special  
20 Purpose Examination, or, at the Board's discretion, a clinical competence assessment program  
21 that meets the criteria of Condition 18 of the current version of the Board's "Manual of Model  
22 Disciplinary Orders and Disciplinary Guidelines" prior to resuming the practice of medicine.

23           Respondent's period of non-practice while on probation shall not exceed two (2) years.

24           Periods of non-practice will not apply to the reduction of the probationary term.

25           Periods of non-practice for a Respondent residing outside of California will relieve  
26 Respondent of the responsibility to comply with the probationary terms and conditions with the  
27 exception of this condition and the following terms and conditions of probation: Obey All Laws;  
28 General Probation Requirements; Quarterly Declarations; Abstain from the Use of Alcohol and/or

1 Controlled Substances; and Biological Fluid Testing.

2 14. COMPLETION OF PROBATION. Respondent shall comply with all financial  
3 obligations (e.g., restitution, probation costs) no later than 120 calendar days prior to the  
4 completion of probation. Upon successful completion of probation, Respondent's certificate shall  
5 be fully restored.

6 15. VIOLATION OF PROBATION. Failure to fully comply with any term or condition  
7 of probation is a violation of probation. If Respondent violates probation in any respect, the  
8 Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and  
9 carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation,  
10 or an Interim Suspension Order is filed against Respondent during probation, the Board shall have  
11 continuing jurisdiction until the matter is final, and the period of probation shall be extended until  
12 the matter is final.

13 16. LICENSE SURRENDER. Following the effective date of this Decision, if  
14 Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy  
15 the terms and conditions of probation, Respondent may request to surrender his or her license.  
16 The Board reserves the right to evaluate Respondent's request and to exercise its discretion in  
17 determining whether or not to grant the request, or to take any other action deemed appropriate  
18 and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent  
19 shall within 15 calendar days deliver Respondent's wallet and wall certificate to the Board or its  
20 designee and Respondent shall no longer practice medicine. Respondent will no longer be subject  
21 to the terms and conditions of probation. If Respondent re-applies for a medical license, the  
22 application shall be treated as a petition for reinstatement of a revoked certificate.


23 17. PROBATION MONITORING COSTS. Respondent shall pay the costs associated  
24 with probation monitoring each and every year of probation, as designated by the Board, which  
25 may be adjusted on an annual basis. Such costs shall be payable to the Medical Board of  
26 California and delivered to the Board or its designee no later than January 31 of each calendar  
27 year.

28 ///

1 **ACCEPTANCE**


2 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully  
3 discussed it with my attorney, Raymond J. McMahon, Esq. I understand the stipulation and the  
4 effect it will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated  
5 Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be  
6 bound by the Decision and Order of the Medical Board of California.

7  
8 DATED: 3/10/2020

  
9 ALAN OGDEN MARCUS, M.D.  
Respondent

10 I have read and fully discussed with Respondent Alan Ogden Marcus, M.D., the terms and  
11 conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order.  
12 I approve its form and content.

13  
14 DATED: 3/11/2020


  
15 RAYMOND J. MCMAHON, ESQ.  
Attorney for Respondent

16  
17 **ENDORSEMENT**

18 The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully  
19 submitted for consideration by the Medical Board of California.

20  
21 DATED: 3/11/2020

Respectfully submitted,  
22 XAVIER BECERRA  
Attorney General of California  
23 ALEXANDRA M. ALVAREZ  
Supervising Deputy Attorney General

  
24 KEITH C. SHAW  
25 Deputy Attorney General  
26 Attorneys for Complainant

27 SD2019701679  
28 72192978.docx

**Exhibit A**

**Accusation No. 800-2016-024668**

1 XAVIER BECERRA  
Attorney General of California  
2 ALEXANDRA M. ALVAREZ  
Supervising Deputy Attorney General  
3 KEITH C. SHAW  
Deputy Attorney General  
4 State Bar No. 227029  
600 West Broadway, Suite 1800  
5 San Diego, CA 92101  
P.O. Box 85266  
6 San Diego, CA 92186-5266  
Telephone: (619) 738-9515  
7 Facsimile: (619) 645-2012

8 *Attorneys for Complainant*

FILED  
STATE OF CALIFORNIA  
MEDICAL BOARD OF CALIFORNIA  
SACRAMENTO *August 23 20 19*  
BY *R. Voong* ANALYST

10 BEFORE THE  
11 MEDICAL BOARD OF CALIFORNIA  
12 DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA

13 In the Matter of the Accusation Against:

Case No. 800-2016-024668

14 **Alan Ogden Marcus, M.D.**

**ACCUSATION**

15 24422 Avenida De La Carlota, Suite 375  
16 Laguna Hills, CA 92653

17 **Physician's and Surgeon's Certificate**  
18 **No. A 39696,**

Respondent.

20  
21 **PARTIES**

22 1. Kimberly Kirchmeyer (Complainant) brings this Accusation solely in her official  
23 capacity as the Executive Director of the Medical Board of California, Department of Consumer  
24 Affairs (Board).

25 2. On or about April 11, 1983, the Medical Board issued Physician's and Surgeon's  
26 Certificate No. A 39696 to Alan Ogden Marcus, M.D. (Respondent). The Physician's and  
27 Surgeon's Certificate was in full force and effect at all times relevant to the charges brought  
28 herein and will expire on April 30, 2021, unless renewed.

1 JURISDICTION

2 3. This Accusation is brought before the Medical Board of California, Department of  
3 Consumer Affairs, under the authority of the following laws. All section references are to the  
4 Business and Professions Code (Code) unless otherwise indicated.

5 4. Section 2227 of the Code states:

6 “(a) A licensee whose matter has been heard by an administrative law judge  
7 of the Medical Quality Hearing Panel as designated in Section 11371 of the  
8 Government Code, or whose default has been entered, and who is found guilty,  
9 or who has entered into a stipulation for disciplinary action with the board, may, in  
10 accordance with the provisions of this chapter:

11 “(1) Have his or her license revoked upon order of the board.

12 “(2) Have his or her right to practice suspended for a period not to exceed  
13 one year upon order of the board.

14 “(3) Be placed on probation and be required to pay the costs of probation  
15 monitoring upon order of the board.

16 “(4) Be publicly reprimanded by the board. The public reprimand may  
17 include a requirement that the licensee complete relevant educational courses approved by  
18 the board.

19 “(5) Have any other action taken in relation to discipline as part of an order  
20 of probation, as the board or an administrative law judge may deem proper.

21 “(b) Any matter heard pursuant to subdivision (a), except for warning letters,  
22 medical review or advisory conferences, professional competency examinations,  
23 continuing education activities, and cost reimbursement associated therewith that  
24 are agreed to with the board and successfully completed by the licensee, or other  
25 matters made confidential or privileged by existing law, is deemed public, and shall be  
26 made available to the public by the board pursuant to Section 803.1.”

27 ///

28 ///



1           5.     Section 2234 of the Code, states:

2           “The board shall take action against any licensee who is charged with unprofessional  
3     conduct. In addition to other provisions of this article, unprofessional conduct includes, but  
4     is not limited to, the following:

5           “... ”

6           “(b) Gross negligence.

7           “(c) Repeated negligent acts. To be repeated, there must be two or more negligent  
8     acts or omissions. An initial negligent act or omission followed by a separate and distinct  
9     departure from the applicable standard of care shall constitute repeated negligent acts.

10          “(1) An initial negligent diagnosis followed by an act or omission medically  
11     appropriate for that negligent diagnosis of the patient shall constitute a single negligent act.

12          “(2) When the standard of care requires a change in the diagnosis, act, or omission  
13     that constitutes the negligent act described in paragraph (1), including, but not limited to, a  
14     reevaluation of the diagnosis or a change in treatment, and the licensee’s conduct departs  
15     from the applicable standard of care, each departure constitutes a separate and distinct  
16     breach of the standard of care.

17          “... ”

18          6.     Section 725 of the Code states:

19          “(a) Repeated acts of clearly excessive prescribing, furnishing, dispensing, or  
20     administering of drugs or treatment, repeated acts of clearly excessive use of  
21     diagnostic procedures, or repeated acts of clearly excessive use of diagnostic or  
22     treatment facilities as determined by the standard of the community of licensees is  
23     unprofessional conduct for a physician and surgeon, dentist, podiatrist,  
24     psychologist, physical therapist, chiropractor, optometrist, speech-language  
25     pathologist, or audiologist.

26          “(b) Any person who engages in repeated acts of clearly excessive  
27     prescribing or administering of drugs or treatment is guilty of a misdemeanor and  
28     shall be punished by a fine of not less than one hundred dollars (\$100) nor more

1 than six hundred dollars (\$600), or by imprisonment for a term of not less than 60  
2 days nor more than 180 days, or by both that fine and imprisonment.

3 “(c) A practitioner who has a medical basis for prescribing, furnishing,  
4 dispensing, or administering dangerous drugs or prescription controlled substances  
5 shall not be subject to disciplinary action or prosecution under this section.

6 “(d) No physician and surgeon shall be subject to disciplinary action pursuant to this  
7 section for treating intractable pain in compliance with Section 2241.5.”

8 7. Section 2266 of the Code states:

9 “The failure of a physician and surgeon to maintain adequate and accurate records  
10 relating to the provision of services to their patients constitutes unprofessional conduct.”

11 8. Section 2229 of the Code states that the protection of the public shall be the highest  
12 priority for the Board in exercising their disciplinary authority. While attempts to rehabilitate a  
13 licensee should be made when possible, Section 2229, subdivision (c), states that when  
14 rehabilitation and protection are inconsistent, protection shall be paramount.

#### 15 PERTINENT DRUGS

16 9. **Ativan**, the trade name for lorazepam, is used for anxiety and sedation in the  
17 management of anxiety disorder for short-term relief from the symptoms of anxiety or anxiety  
18 associated with depressive symptoms. It is a dangerous drug as defined in section 4022 and a  
19 Schedule IV controlled substance as defined by section 11057 of the Health and Safety Code.  
20 Lorazepam is not recommended for use in patients with primary depressive disorders. Sudden  
21 withdrawal from lorazepam can produce withdrawal symptoms including seizures.

22 10. **Diazepam**, known by the trade name Valium, is a medicine of the benzodiazepine  
23 class of drugs commonly used to treat anxiety, alcohol withdrawal, and seizures. It is a dangerous  
24 drug as defined in Business and Professions Code section 4022 and a schedule IV controlled  
25 substance as defined by section 11057 of the Health and Safety Code. It produces central nervous  
26 system depression and should be used with caution with other central nervous system depressant  
27 drugs. Like other benzodiazepines, it can produce psychological and physical dependence.  
28 Withdrawal symptoms similar to those noted with barbiturates and alcohol have been noted upon

1 abrupt discontinuance. The Drug Enforcement Administration (DEA) has identified  
2 benzodiazepines, such as diazepam, as a drug of abuse. (Drugs of Abuse, DEA Resource Guide  
3 (2011 Edition), at p. 53.)

4 11. **Fentanyl** (Actiq, Fentora, and Duragesic) is a powerful synthetic opioid that is  
5 similar to morphine but is 50 to 100 times more potent. Like morphine, it is a medication  
6 ordinarily used to treat patients with severe pain, especially after surgery. When properly  
7 prescribed and indicated, fentanyl is at times used for the management of pain in opioid-tolerant  
8 patients, severe enough to require daily, continuous, long term opioid treatment, and for which  
9 alternative treatment options are inadequate. Fentanyl is a Schedule II controlled substance  
10 pursuant to Health and Safety Code section 11055, subdivision (c), and a dangerous drug  
11 pursuant to Business and Professions Code section 4022. The FDA has issued several black box  
12 warnings about fentanyl, including, but not limited to, the risks of addiction, abuse and misuse;  
13 life threatening respiratory depression; accidental exposure; neonatal opioid withdrawal  
14 syndrome; and the risks associated with the concomitant use with benzodiazepines or other CNS  
15 depressants. Fentanyl comes in several forms, including as an injection, intrathecal  
16 administration (an injection around the spinal canal), a transdermal patch that is placed on the  
17 skin, or as a lozenge that is sucked like a cough drop (Actiq).

18 12. **Hydrocodone APAP** (Vicodin, Lortab, and Norco) is a hydrocodone combination of  
19 hydrocodone bitartrate and acetaminophen which was formerly a Schedule III controlled  
20 substance pursuant to Health and Safety Code section 11056, subdivision (e), and a dangerous  
21 drug pursuant to Business and Professions Code section 4022. On August 22, 2014, the DEA  
22 published a final rule rescheduling hydrocodone combination products (HCP's) to schedule II of  
23 the Controlled Substances Act, which became effective October 6, 2014. Schedule II controlled  
24 substances are substances that have a currently accepted medical use in the United States, but also  
25 have a high potential for abuse, and the abuse of which may lead to severe psychological or  
26 physical dependence. When properly prescribed and indicated, HCP's are used for the treatment  
27 of moderate to severe pain. In addition to the potential for psychological and physical  
28 dependence there is also the risk of acute liver failure which has resulted in a black box warning

1 being issued by the Federal Drug Administration (FDA). The FDA black box warning provides  
2 that “[a]cetaminophen has been associated with cases of acute liver failure, at times resulting in  
3 liver transplant and death. Most of the cases of liver injury are associated with use of the  
4 acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one  
5 acetaminophen containing product.”

6 13. **MS Contin** (morphine sulfate), an opioid analgesic, is a Schedule II controlled  
7 substance pursuant to Health and Safety Code section 11055, subdivision (e), and a dangerous  
8 drug pursuant to Business and Professions Code section 4022. When properly prescribed and  
9 indicated, it is used for the management of pain that is severe enough to require daily, around-the-  
10 clock, long-term opioid treatment and for which alternative treatment options are inadequate. The  
11 Drug Enforcement Administration has identified MS Contin, as a drug of abuse. (Drugs of  
12 Abuse, A DEA Resource Guide (2011 Edition), at p. 39.) The Federal Drug Administration has  
13 issued a black box warning for MS Contin which warns about, among other things, addiction,  
14 abuse and misuse, and the possibility of life-threatening respiratory distress.

15 14. **Oxycodone with acetaminophen** (Percocet), an opioid analgesic, is a Schedule II  
16 controlled substance pursuant to Health and Safety Code section 11055, subdivision (b), and a  
17 dangerous drug pursuant to Business and Professions Code section 4022. When properly  
18 prescribed and indicated, it is used for the management of moderate to moderately severe pain.  
19 The Drug Enforcement Administration has identified oxycodone, as a drug of abuse. (Drugs of  
20 Abuse, A DEA Resource Guide (2011 Edition), at p. 41.) The Federal Drug Administration has  
21 issued a black box warning for Percocet which warns about, among other things, addiction, abuse  
22 and misuse, and the possibility of “life-threatening respiratory distress.”

23 15. **Oxycodone HCL** (OxyContin) is a Schedule II controlled substance pursuant to  
24 Health and Safety Code section 11055, subdivision (b), and a dangerous drug pursuant to  
25 Business and Professions Code section 4022. When properly prescribed and indicated,  
26 OxyContin is used for the management of pain severe enough to require daily, around-the-clock,  
27 long term opioid treatment for which alternative treatment options are inadequate. The DEA has  
28 identified OxyContin as a drug of abuse. (Drugs of Abuse, A DEA Resource Guide (2011

1 Edition), at p. 41.) The risk of respiratory depression and overdose is increased with the  
2 concomitant use of benzodiazepines or when prescribed to patients with pre-existing respiratory  
3 depression.

4 16. **Provigil** (modafinil), a stimulant, is a Schedule IV controlled substance pursuant to  
5 Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to  
6 Business and Professions Code section 4022. When properly prescribed and indicated, it is used  
7 to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy,  
8 obstructive sleep apnea, or shift work disorder.

9 17. **Temazepam** (Restoril), a benzodiazepine, is a centrally acting hypnotic-sedative that  
10 is a Schedule IV controlled substance pursuant to Health and Safety Code section 11057,  
11 subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.  
12 When properly prescribed and indicated, it is used to treat seizure disorders and panic disorders.  
13 Concomitant use of Restoril with opioids “may result in profound sedation, respiratory  
14 depression, coma, and death.” The Drug Enforcement Administration (DEA) has identified  
15 benzodiazepines, such as Restoril, as a drug of abuse. (Drugs of Abuse, DEA Resource Guide  
16 (2011 Edition), at p. 53.)

17 18. **Xanax** (alprazolam), a benzodiazepine, is a centrally acting hypnotic-sedative that is  
18 a Schedule IV controlled substance pursuant to Health and Safety Code section 11057,  
19 subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.  
20 When properly prescribed and indicated, it is used for the management of anxiety disorders.  
21 Concomitant use of Xanax with opioids “may result in profound sedation, respiratory depression,  
22 coma, and death.” The DEA has identified benzodiazepines, such as Xanax, as a drug of abuse.  
23 (Drugs of Abuse, DEA Resource Guide (2011 Edition), at p. 53.)

24 **FIRST CAUSE FOR DISCIPLINE**

25 **(Gross Negligence)**

26 19. Respondent is subject to disciplinary action under sections 2227 and 2234, as defined  
27 by section 2234, subdivision (b), of the Code, in that he committed gross negligence in his care  
28 and treatment of patients A, B, C, D, E, and F, as more particularly alleged hereinafter:

1           PATIENT A

2           20. Respondent began treatment with Patient A,<sup>1</sup> a then-19-year old female, on or about  
3 February 20, 2014. The patient presented with numerous medical conditions, including  
4 hypopituitary and hypoadrenal issues, polycystic ovarian syndrome, thyroid disease, and  
5 autoimmune diseases.

6           21. On or about May 28, 2014, Respondent began prescribing Vicodin (325 mg  
7 acetaminophen/5 mg hydrocodone) to Patient A on a monthly basis. The dosage of Vicodin  
8 increased to 325/10 mg on or about August 25, 2014. While regularly prescribing Vicodin,  
9 Respondent also began prescribing Percocet (325 mg acetaminophen/5 mg oxycodone) on or  
10 about September 3, 2014. Between approximately September 25, 2014 and November 18, 2014,  
11 Respondent concurrently issued prescriptions for numerous opioids and benzodiazepines,  
12 including Percocet,<sup>2</sup> Vicodin, OxyContin, Fentanyl, lorazepam,<sup>3</sup> zolpidem, and diazepam.  
13 During this time, Respondent had no formal training in pain management,<sup>4</sup> and prescribed  
14 multiple opioids concurrently with benzodiazepines without documenting the following: a  
15 specific diagnosis for which opiate treatment was required, informed consent, a treatment plan  
16 with objectives, periodic reviews, referral to a specialist when indicated, and monitoring of  
17 patient compliance with the prescribed medication.

18           22. On or about October 29, 2014, Respondent prescribed Fentanyl patches without  
19 documenting a diagnosis or treatment plan. On or about October 8, 2014, Respondent prescribed  
20 Oxycodone with only a reference to "LS Cervical pain" in the notes, and without documenting a  
21 physical examination or future treatment plan. On or about May 19, 2015, Respondent prescribed  
22 Ativan with no clear diagnosis or treatment plan. On or about July 30, 2015, Respondent  
23

24           <sup>1</sup> The patients listed in this document are unnamed to protect their privacy. Respondent  
25 knows the name of the patients and can confirm their identity through discovery.

26           <sup>2</sup> Three Percocet prescriptions for 305 total tablets during this time period.

27           <sup>3</sup> Two Ativan prescriptions for 100 total tablets during this time period.

28           <sup>4</sup> Respondent's only formal training in pain management did not occur until the spring of  
2018 according to an interview conducted on March 19, 2019.

1 prescribed OxyContin 60 mg/day at the same time Patient A was receiving regular prescriptions  
2 for benzodiazepines.

3 23. In an interview on or about March 19, 2019, Respondent indicated that he only  
4 prescribed pain medicine to Patient A after consulting with and at the request of another  
5 physician, but there lacks any documentation to that effect. Respondent admitted that long-term  
6 opiate patients require a higher level of care, however, he failed to refer Patient A to an  
7 appropriate pain or addiction specialist during the course of treatment. During Respondent's care  
8 of Patient A from 2014 through 2017, Respondent did not use an electronic medical records  
9 system. His typical medical note was a single page of handwritten words that were largely  
10 illegible, and diagnoses and treatment plans were not readily apparent.

11 24. Respondent committed gross negligence in his care and treatment of Patient A which  
12 included, but was not limited to, the following:

- 13 (a) Respondent failed to establish a clear diagnosis for which opiate  
14 usage was required;
- 15 (b) Respondent failed to obtain informed consent for opiate therapy and  
16 the concurrent use of opioids with benzodiazepines;
- 17 (c) Respondent failed to document a detailed treatment plan with  
18 objectives and aims to be achieved when starting or continuing opioid  
19 therapy;
- 20 (d) Respondent failed to document formal periodic reviews detailing the  
21 safety and efficacy of treatment with opioid medication;
- 22 (e) Respondent did not take appropriate steps to monitor for medication  
23 compliance, such as random urine screens, blood samples, review of  
24 CURES, updated history and physical examination;
- 25 (f) Respondent failed to timely refer the patient to an appropriate pain  
26 specialist; and
- 27 (g) Respondent failed to record adequate and clear medical  
28 documentation.

1            PATIENT B

2            25. Respondent started treating Patient B, a then-60-year old male, in approximately June  
3 2003.<sup>5</sup> The patient presented with a history of diabetes, lymphoma, thyroid disease, surgically  
4 repaired hand trauma, coronary artery disease, as well as other medical conditions. At his initial  
5 office visit, Patient B was under the case of three separate pain management physicians and  
6 several other specialist physicians. Respondent assumed case for many of Patient B's medical  
7 conditions and began prescribing him with numerous opioid pain medications.

8            26. Respondent prescribed numerous long-term opioids to Patient B concurrently with  
9 benzodiazepines. During the time period from approximately November 2013 through April  
10 2017, Respondent prescribed Patient B with the following controlled substances on a recurring  
11 monthly basis:<sup>6</sup> Norco, 325/10 mg (#360), OxyContin 40 mg (#60), and temazepam 15 mg (#30).  
12 During this time, Respondent failed to document the following: an indication for which opiate  
13 therapy was required, informed consent, a treatment plan with objectives, periodic reviews, and  
14 monitoring of patient compliance with the prescribed medication. On or about November 15,  
15 2015, Respondent prescribed Norco and OxyContin to Patient B without any corresponding office  
16 note for that date.

17            27. In an interview on or about March 19, 2019, Respondent admitted that long-term  
18 opiate use in an elderly patient such as Patient B<sup>7</sup> could cause him to "die" or go into "respiratory  
19 depression." Respondent understood that patients receiving dosages above 90 morphine  
20 milligram equivalent (MME) have a higher risk of an adverse event. However, from  
21 approximately November 2013 through April 2017, Respondent prescribed Patient B well in  
22 excess of 200 MME on a daily basis. At no time during this period did Respondent refer Patient  
23 B to a pain or addiction specialist even though he had no formal training in pain management. In

24 \_\_\_\_\_  
25 <sup>5</sup> Conduct occurring more than seven (7) years from the filing date of this Accusation is  
for informational purposes only and is not alleged as a basis for disciplinary action.

26 <sup>6</sup> At times, some prescriptions were issued at intervals shorter than one month and longer  
27 than one month.

28 <sup>7</sup> Patient B was 72-years-old in 2016, the same time he was being prescribed substantial  
doses of opioids and benzodiazepines concurrently.



1 approximately March 2017, Respondent prescribed 60 tablets of OxyContin 40 mg and 480  
2 tablets of Norco 325/10 mg, which equates to 280 MME daily over the course of the month, over  
3 three times the MME amount that should have prompted consideration of referral to a specialist.  
4 This pattern of high dose opioid therapy occurred while Respondent was concurrently prescribing  
5 benzodiazepines, not ordering urine drug screenings, and not checking CURES reports.

6 28. During Respondent's care of Patient B from 2014 through 2017, Respondent did not  
7 use an electronic medical records system. His typical medical note was a single page of  
8 handwritten words or notations that were largely illegible, and diagnoses and treatment plans  
9 were not readily apparent.

10 29. Respondent committed gross negligence in his care and treatment of Patient B which  
11 included, but was not limited to, the following:

- 12 (a) Respondent failed to establish a clear diagnosis for which opiate  
13 usage was required;
- 14 (b) Respondent failed to obtain informed consent for opiate therapy and  
15 the concurrent use of opioids with benzodiazepines;
- 16 (c) Respondent failed to document a detailed treatment plan with  
17 objectives and aims to be achieved when starting or continuing opioid  
18 therapy;
- 19 (d) Respondent failed to document formal periodic reviews detailing the  
20 safety and efficacy of treatment with opioid medication;
- 21 (e) Respondent did not take appropriate steps to monitor for medication  
22 compliance, such as random urine screens, blood samples, review of  
23 CURES, updated history and physical examination;
- 24 (f) Respondent failed to timely refer the patient to an appropriate pain  
25 specialist; and
- 26 (g) Respondent failed to record adequate and clear medical  
27 documentation.

1           PATIENT C

2           30. Respondent began treating Patient C, a then-63-year old female, in approximately  
3 June 2005. The patient had a history of SIADH,<sup>8</sup> psoriatic arthritis, chronic pulmonary disease,  
4 frozen shoulder, ruptured tendons, anemia, hypertension, glaucoma, hypothyroidism, myocarditis  
5 from Coxsackie infection, and immunological issues. During the time period from approximately  
6 August 2013 through February 2017, Respondent prescribed Patient C with significant doses of  
7 controlled substances on a recurring monthly basis,<sup>9</sup> including Norco 325/10 mg (#240) and  
8 Provigil 200 mg (#60). During this time, Respondent failed to document the following: a specific  
9 diagnosis for which opiate use was required, informed consent, a discussion of side effects,  
10 justification of dosage, a treatment plan with objectives, periodic reviews evaluating the  
11 effectiveness of the medication, referral to a specialist when indicated, and monitoring of patient  
12 compliance with the prescribed medication.

13           31. On or about February 22, 2017, Respondent prescribed Provigil 800 mg/day,  
14 however, there lacks any documentation from the office note on the same date regarding the use,  
15 indication, or rationale for prescribing that medication. The dosage for Provigil of 800 mg/day  
16 far exceeds the typical dosage of 200 mg/day, but there is no explanation for this excessive  
17 dosage in the medical note. Given Patient C's long-term, high dosage of Provigil, in conjunction  
18 with the long-term, high dosage of Norco (which included 80 mg per day of hydrocodone),  
19 Patient C's daily MME far exceeded the 90 MME dosage level that Respondent understood  
20 created a higher risk of an adverse event in patients, and should have prompted referral to a  
21 specialist. Moreover, Respondent had no formal training in pain management during this time.

22           32. During Respondent's care of Patient C from 2014 through 2017, Respondent did not  
23 use an electronic medical records system. His typical medical note was a single page of  
24 handwritten words or notations that were largely illegible, and diagnoses and treatment plans  
25 were not readily apparent.

26           <sup>8</sup> Syndrome of inappropriate antidiuretic hormone secretion (SIADH).

27           <sup>9</sup> At times, some prescriptions were issued at intervals shorter than one month and longer  
28 than one month.

1 33. Respondent committed gross negligence in his care and treatment of Patient C which  
2 included, but was not limited to, the following:

3 (a) Respondent failed to establish a clear diagnosis for which opiate  
4 usage was required;

5 (b) Respondent failed to obtain informed consent for opiate therapy;

6 (c) Respondent failed to document a detailed treatment plan with  
7 objectives and aims to be achieved when starting or continuing opioid  
8 therapy;

9 (d) Respondent failed to document formal periodic reviews detailing the  
10 safety and efficacy of treatment with opioid medication;

11 (e) Respondent did not take appropriate steps to monitor for medication  
12 compliance, such as random urine screens, blood samples, review of  
13 CURES, updated history and physical examination;

14 (f) Respondent failed to timely refer the patient to an appropriate pain  
15 specialist; and

16 (g) Respondent failed to record adequate and clear medical  
17 documentation.

18 **PATIENT D**

19 34. Respondent began treating Patient D, a then-43-year old female, in approximately  
20 1997 for "multiple things that were going on," according to Respondent.<sup>10</sup> During the time period  
21 from approximately July 2013 through February 2017, Respondent prescribed Patient D with  
22 significant doses of controlled substances on a recurring monthly basis,<sup>11</sup> including OxyContin  
23 80 mg (#90) and alprazolam 2 mg (#210). During this time, Respondent had no formal training in  
24 pain management and failed to document the following: a specific diagnosis for which opiate use  
25

26 <sup>10</sup> Medical records were not located by Respondent for Patient D, but according to his  
27 March 19, 2019, interview, she was being treated for "multiple things."

28 <sup>11</sup> At times, some prescriptions were issued at intervals shorter than one month and longer  
than one month.

1 was required, informed consent, a discussion of side effects, justification of dosage, a treatment  
2 plan with objectives, periodic reviews evaluating the effectiveness of the medication, and  
3 monitoring of patient compliance with the prescribed medication.

4 35. Between approximately July 2013 and February 2017, Respondent at times  
5 prescribed opiates in the range of 360 MME, four times the amount that Respondent understood  
6 created a higher risk of an adverse event in patients. There was no documentation that  
7 Respondent attempted to wean Patient D from controlled substances, attempted alternative  
8 medications and therapies, or considered referral to a pain specialist. In Respondent's Board  
9 interview, he indicated that "I have voluminous charts on her," but he was unable to provide any  
10 medical records for Patient D.

11 36. Respondent committed gross negligence in his care and treatment of Patient D which  
12 included, but was not limited to, the following:

- 13 (a) Respondent prescribed long term, high dose opiates and  
14 benzodiazepines concurrently while not being a pain specialist;
- 15 (b) Respondent failed to document an adequate history and physical  
16 examination;
- 17 (c) Respondent failed to establish a clear diagnosis for which opiate  
18 usage was required;
- 19 (d) Respondent failed to obtain informed consent for opiate therapy and  
20 the concurrent use of opioids with benzodiazepines;
- 21 (e) Respondent failed to document a detailed treatment plan with  
22 objectives and aims to be achieved when starting or continuing opioid  
23 therapy;
- 24 (f) Respondent failed to document formal periodic reviews detailing the  
25 safety and efficacy of treatment with opioid medication;
- 26 (g) Respondent did not take appropriate steps to monitor for medication  
27 compliance, such as random urine screens, blood samples, review of  
28 CURES, updated history and physical examination;

1 (h) Respondent failed to timely refer the patient to an appropriate pain  
2 specialist; and

3 (i) Respondent failed to maintain and make available Patient D's medical  
4 records.

5 **PATIENT E**

6 37. Respondent's initial treatment with Patient E, a then-69-year old male, occurred since  
7 at least 2014. He suffered from diabetes, hypertension, gout, and obesity. During the time period  
8 from approximately December 2014 through October 2016, Respondent prescribed Patient E with  
9 significant doses of opioids on a recurring monthly basis,<sup>12</sup> including Norco 325/10 mg (#120)  
10 and MS Contin 100 mg (#90).<sup>13</sup> During this time, Respondent had no formal training in pain  
11 management and failed to document the following: a specific diagnosis for which opiate use was  
12 required, informed consent, a discussion of side effects, justification of dosage, a treatment plan  
13 with objectives, periodic reviews evaluating the effectiveness of the medication, referral to a  
14 specialist when indicated, and monitoring of patient compliance with the prescribed medication.

15 38. Between approximately December 2014 and October 2016, Respondent prescribed  
16 Patient E with opiates at a substantial level of approximately 360 MME, yet there is no  
17 documentation that Respondent referred the patient to a pain specialist. On or about March 2,  
18 2015, Respondent issued a prescription for Norco, yet the corresponding office note lists only  
19 Patient E's name and date while the remainder of the form is left completely blank.

20 39. During Respondent's care of Patient E from 2014 through 2017, Respondent did not  
21 use an electronic medical records system. His typical medical note was a single page of  
22 handwritten words or notations that were largely illegible, and diagnoses and treatment plans  
23 were not readily apparent.

24  
25  
26 <sup>12</sup> At times, some prescriptions were issued at intervals shorter than one month and longer  
than one month.

27 <sup>13</sup> Between approximately December 2014 and October 2016, Respondent prescribed on  
28 average 40mg of hydrocodone and 300-400 mg of morphine to Patient E.

1           40. Respondent committed gross negligence in his care and treatment of Patient E which  
2 included, but was not limited to, the following:

- 3                   (a) Respondent failed to establish a clear diagnosis for which opiate  
4                   usage was required;
- 5                   (b) Respondent failed to obtain informed consent for opiate therapy;
- 6                   (c) Respondent failed to document a detailed treatment plan with  
7                   objectives and aims to be achieved when starting or continuing opioid  
8                   therapy;
- 9                   (d) Respondent failed to document formal periodic reviews detailing the  
10                  safety and efficacy of treatment with opioid medication;
- 11                  (e) Respondent did not take appropriate steps to monitor for medication  
12                  compliance, such as random urine screens, blood samples, review of  
13                  CURES, updated history and physical examination;
- 14                  (f) Respondent failed to timely refer the patient to an appropriate pain  
15                  specialist; and
- 16                  (g) Respondent failed to record adequate and clear medical  
17                  documentation.

18           **PATIENT F**

19           41. Respondent began treating Patient F, a then-51-year old female, since at least 2013.  
20 She had a history of diabetes, depression, vaginal dryness, hepatitis C, and migraine headaches.  
21 During the time period from approximately December 2013 through January 2017, Respondent  
22 prescribed Patient F with substantial doses of opioids and benzodiazepines on a recurring monthly  
23 basis,<sup>14</sup> including Vicodin 325/7.5 mg and alprazolam.<sup>15</sup> During this time, Respondent had no  
24 formal training in pain management and failed to document the following: a specific diagnosis for  
25

26                   <sup>14</sup> At times, some prescriptions were issued at intervals shorter than one month and longer  
27                   than one month.

28                   <sup>15</sup> Prescriptions for alprazolam were initially prescribed for 0.5 mg in 2013 until on or  
                    about March 4, 2015, at which time the dosage permanently increased to 2 mg.

1 which opiate use was required, informed consent, a discussion of side effects, justification of  
2 dosage, a treatment plan with objectives, periodic reviews evaluating the effectiveness of the  
3 medication, referral to a specialist when indicated, attempts to wean controlled substances, and  
4 monitoring of patient compliance with the prescribed medication.

5 42. During Respondent's care of Patient F from 2014 through 2017, Respondent did not  
6 use an electronic medical records system. His typical medical note was a single page of  
7 handwritten words or notations that were largely illegible, and diagnoses and treatment plans  
8 were not readily apparent.

9 43. Respondent committed gross negligence in his care and treatment of Patient F which  
10 included, but was not limited to, the following:

- 11 (a) Respondent failed to establish a clear diagnosis for which opiate  
12 usage was required;
- 13 (b) Respondent failed to obtain informed consent for opiate therapy and  
14 the concurrent use of opioids with benzodiazepines;
- 15 (c) Respondent failed to document a detailed treatment plan with  
16 objectives and aims to be achieved when starting or continuing opioid  
17 therapy;
- 18 (d) Respondent failed to document formal periodic reviews detailing the  
19 safety and efficacy of treatment with opioid medication;
- 20 (e) Respondent did not take appropriate steps to monitor for medication  
21 compliance, such as random urine screens, blood samples, review of  
22 CURES, updated history and physical examination;
- 23 (f) Respondent failed to timely refer the patient to an appropriate pain  
24 specialist; and
- 25 (g) Respondent failed to record adequate and clear medical  
26 documentation.

27 ///

28 ///

1 **SECOND CAUSE FOR DISCIPLINE**

2 **(Repeated Negligent Acts)**

3 44. Respondent is further subject to disciplinary action under sections 2227 and 2234, as  
4 defined by section 2234, subdivision (c), of the Code, in that he committed repeated negligent  
5 acts in his care and treatment of patients A, B, C, D, E, and F, as more particularly alleged in  
6 paragraphs 19 through 43, above, which are hereby incorporated by reference and realleged as if  
7 fully set forth herein.

8 **THIRD CAUSE FOR DISCIPLINE**

9 **(Repeated Acts of Clearly Excessive Prescribing)**

10 45. Respondent is further subject to disciplinary action under sections 2227 and 2234, as  
11 defined by section 725, of the Code, in that he has committed repeated acts of clearly excessive  
12 prescribing of drugs or treatment to patients A, B, C, D, E, and F, as determined by the standard  
13 of the community of physicians, as more particularly alleged in paragraphs 19 through 43, above,  
14 which are hereby incorporated by reference and realleged as if fully set forth herein.

15 **FOURTH CAUSE FOR DISCIPLINE**

16 **(Failure to Maintain Adequate and Accurate Records)**

17 46. Respondent is further subject to disciplinary action under sections 2227 and 2234, as  
18 defined by section 2266, of the Code, in that Respondent failed to maintain adequate and accurate  
19 records regarding his care and treatment of patients A, B, C, D, E, and F, as more particularly  
20 alleged in paragraphs 19 through 43, above, which are hereby incorporated by reference and  
21 realleged as if fully set forth herein.

22 **DISCIPLINARY CONSIDERATIONS**

23 47. To determine the degree of discipline, if any, to be imposed on Respondent Alan  
24 Ogden Marcus, M.D., Complainant alleges that on or about February 28, 2014, in a prior  
25 disciplinary action entitled *In the Matter of the Accusation Against Alan Ogden Marcus, M.D.*,  
26 before the Medical Board of California, in Case No. 04-2011-214937, Respondent's license was  
27 placed on probation for three years with terms and conditions for the following:  
28




1 (1) Unprofessional Conduct; and (2) Dangerous Use of Drugs. That decision is now final and is  
2 incorporated by reference as if fully set forth herein.

3 PRAYER

4 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,  
5 and that following the hearing, the Medical Board of California issue a decision:

- 6 1. Revoking or suspending Physician's and Surgeon's Certificate No. A 39696, issued  
7 to Alan Ogden Marcus, M.D.;
- 8 2. Revoking, suspending or denying approval of Alan Ogden Marcus, M.D.'s authority  
9 to supervise physician assistants and advanced practice nurses;
- 10 3. Ordering Alan Ogden Marcus, M.D., if placed on probation, to pay the Board the  
11 costs of probation monitoring; and
- 12 4. Taking such other and further action as deemed necessary and proper.

13  
14 DATED: August 23, 2019

  
KIMBERLY KIRCHMEYER  
Executive Director  
Medical Board of California  
Department of Consumer Affairs  
State of California  
*Complainant*

15  
16  
17  
18  
19  
20 SD2019701679  
71943061